SLC1A7: A promising drug target for treating neurodegenerative diseases

Target Name: SLC1A7

NCBI ID: G6512

SLC1A7

SLC1A7: A promising drug target for treating neurodegenerative diseases

SLC1A7, or selectin protein 1A7, is a transmembrane protein that plays a crucial role in the regulation of neurotransmitter transport in the central nervous system (CNS). It is expressed in various tissues, including the brain, and is involved in the transmembrane transport of several neurotransmitters, including glutamate, a key neurotransmitter involved in learning, memory, and synaptic plasticity.

Several neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of neurons and their associated neurotransmitter synthesis and function. Therefore, targeting SLC1A7 and its associated neurotransmitters could provide new therapeutic options for these debilitating diseases.

Drug targeting SLC1A7

SLC1A7 has been identified as a potential drug target for several neurodegenerative diseases due to its involvement in the regulation of neurotransmitter transport. Several studies have shown that modulating SLC1A7 function could be a promising strategy for treating neurodegenerative diseases.

1. Neuronal dysfunction and neurotransmitter synthesis

SLC1A7 is involved in the transmembrane transport of several neurotransmitters, including glutamate, which is essential for synaptic plasticity and learning. In addition, SLC1A7 is also involved in the transmembrane transport of other neurotransmitters, such as GABA, serotonin, and dopamine.

Studies have shown that SLC1A7 dysfunction is associated with neuronal dysfunction and neurotransmitter synthesis disorders, which are key features of neurodegenerative diseases. For example, SLC1A7-deficient mice have been shown to have increased neuronal excitability and decreased neurotransmitter synthesis, suggesting that modulating SLC1A7 function could be a potential therapeutic approach for neurodegenerative diseases.

1. The role of SLC1A7 in neurotransmitter synthesis and function

SLC1A7 is involved in the transmembrane transport of several neurotransmitters, including glutamate, which is a key neurotransmitter involved in learning, memory, and synaptic plasticity. Glutamate is synthesized in the brain and is involved in the regulation of neural activity, including synaptic plasticity and learning.

Studies have shown that SLC1A7 is involved in the regulation of glutamate synthesis and function. For example, SLC1A7 has been shown to be a critical transporter for the synthesis of glutamate in the brain. Additionally, SLC1A7 has been shown to play a role in the regulation of glutamate receptor function, which is involved in synaptic plasticity and learning.

1. The potential clinical applications of SLC1A7 targeting

The potential clinical applications of SLC1A7 targeting are vast, as SLC1A7 is involved in the regulation of neurotransmitter synthesis and function in the brain. Targeting SLC1A7 function could provide new therapeutic options for treating neurodegenerative diseases.

One potential approach to SLC1A7 targeting is drug development targeting SLC1A7 itself, either through small molecules or antibodies. Small molecules that target SLC1A7 function have been shown to be effective in modulating neurotransmitter synthesis and function in the brain. For example, inhibitors of SLC1A7 have been shown to be effective in reducing neurotransmitter synthesis and increasing neurotransmitter release in the brain, which could be a potential therapeutic approach for

Protein Name: Solute Carrier Family 1 Member 7

Functions: Sodium-dependent, high-affinity amino acid transporter that mediates the uptake of L-glutamate and also L-aspartate and D-aspartate. Functions as a symporter that transports one amino acid molecule together with two or three Na(+) ions and one proton, in parallel with the counter-transport of one K(+) ion (PubMed:9108121). Acts primarily as an inhibitory glutamate-gated chloride channel being a major inhibitory presynaptic receptor at mammalian rod bipolar cell axon terminals. Glutamate binding gates a large Cl(-) conductance that mediates inhibition, affecting visual processing in the retina (By similarity)

The "SLC1A7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC1A7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets